tiprankstipranks
Trending News
More News >
Welby Inc. (JP:4438)
:4438
Japanese Market
Advertisement

Welby Inc. (4438) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4438

Welby Inc.

(4438)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
¥328.00
▲(10.81% Upside)
The overall stock score is primarily influenced by financial performance challenges, including declining revenues and persistent losses. Technical analysis provides some neutral signals, but valuation remains poor due to negative earnings. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Business Model Strength
The SaaS model provides steady, predictable revenue through subscription fees, enhancing long-term financial stability and customer retention.
Market Position
Specialization in healthcare tech positions Welby Inc. to capitalize on growing demand for digital health solutions, supporting sustained market relevance.
Partnerships
Strategic partnerships enhance product offerings and market penetration, fostering growth and competitive advantage in the healthcare sector.
Negative Factors
Revenue Decline
Declining revenue indicates potential market challenges or competitive pressures, threatening long-term growth and financial health.
Cash Flow Issues
Persistent cash flow issues can limit operational flexibility and investment capacity, hindering future growth and stability.
Profitability Challenges
Ongoing profitability challenges highlight operational inefficiencies, impacting long-term viability and shareholder value.

Welby Inc. (4438) vs. iShares MSCI Japan ETF (EWJ)

Welby Inc. Business Overview & Revenue Model

Company DescriptionWelby Inc. (4438) is a technology-driven company that specializes in providing innovative solutions in the healthcare sector. The company focuses on developing software applications and platforms that enhance patient engagement, improve healthcare delivery, and streamline clinical workflows. With a commitment to leveraging data analytics and artificial intelligence, Welby Inc. aims to empower healthcare providers and patients alike through its core products, which include healthcare management systems, telemedicine solutions, and patient monitoring tools.
How the Company Makes MoneyWelby Inc. generates revenue primarily through the sale of its software solutions and subscription-based services. The company operates on a SaaS (Software as a Service) model, where healthcare organizations pay a recurring fee to access and utilize its platforms. Key revenue streams include licensing fees for its software products, subscription fees for ongoing service and support, and fees for additional features or modules that customers can opt to integrate into their existing systems. Additionally, Welby Inc. has established partnerships with healthcare providers and technology firms to expand its market reach and enhance its product offerings, which contribute significantly to its earnings.

Welby Inc. Financial Statement Overview

Summary
Welby Inc. is facing financial challenges with declining revenues and persistent losses. Despite a strong equity position, the company struggles with cash flow generation and operational efficiency, necessitating a focus on improving profitability and cash flow.
Income Statement
35
Negative
Welby Inc. has experienced a significant decline in revenue over the past few years, with a notable drop from 2022 to 2023. The company has consistently reported negative net income, indicating ongoing profitability challenges. The gross profit margin remains relatively strong, but the negative EBIT and EBITDA margins highlight operational inefficiencies.
Balance Sheet
55
Neutral
The company's balance sheet shows a strong equity position with a high equity ratio, indicating financial stability. However, the debt-to-equity ratio has increased slightly, which could pose a risk if the trend continues. The return on equity is negative due to consistent net losses, impacting overall shareholder value.
Cash Flow
40
Negative
Welby Inc. has faced challenges in generating positive operating cash flow, with significant negative free cash flow over the years. The operating cash flow to net income ratio is unfavorable, reflecting difficulties in converting earnings into cash. The free cash flow to net income ratio is also negative, indicating cash flow issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue630.81M528.04M575.00M1.05B1.14B864.64M
Gross Profit455.08M379.92M376.00M755.44M683.91M506.30M
EBITDA-564.74M-792.75M-499.97M40.29M-127.70M-309.28M
Net Income-744.65M-804.60M-505.00M33.91M-130.68M-353.09M
Balance Sheet
Total Assets966.27M1.17B1.21B1.40B1.39B1.52B
Cash, Cash Equivalents and Short-Term Investments567.83M740.43M883.00M830.82M960.72M1.10B
Total Debt235.00M200.00M1.00M8.35M15.49M22.63M
Total Liabilities365.43M328.90M88.00M121.40M134.83M162.60M
Stockholders Equity565.27M810.02M1.09B1.27B1.26B1.36B
Cash Flow
Free Cash Flow0.00-776.25M-177.00M-146.86M-115.46M-155.09M
Operating Cash Flow0.00-603.63M-174.00M-114.11M-95.95M-110.97M
Investing Cash Flow0.00-235.84M-114.39M-7.04M-34.56M-19.48M
Financing Cash Flow0.00696.54M341.25M-8.74M-7.14M20.00M

Welby Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price296.00
Price Trends
50DMA
316.66
Negative
100DMA
331.14
Negative
200DMA
335.21
Negative
Market Momentum
MACD
-2.14
Positive
RSI
44.92
Neutral
STOCH
2.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4438, the sentiment is Negative. The current price of 296 is below the 20-day moving average (MA) of 327.25, below the 50-day MA of 316.66, and below the 200-day MA of 335.21, indicating a bearish trend. The MACD of -2.14 indicates Positive momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 2.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4438.

Welby Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥3.26B13.051.90%6.68%2.86%
67
Neutral
¥25.94B23.351.32%9.85%20.83%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
¥2.39B-3.2016.19%-4.42%
45
Neutral
¥15.55B39.30%32.06%
45
Neutral
¥3.57B-13.001.51%-13.66%
43
Neutral
¥17.43B-23.821.33%6.17%-8918.66%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4438
Welby Inc.
296.00
-79.00
-21.07%
JP:3902
Medical Data Vision Co.Ltd.
487.00
50.62
11.60%
JP:3939
Kanamic Network Co., LTD.
569.00
83.58
17.22%
JP:4263
SUSMED,Inc.
945.00
347.00
58.03%
JP:6034
MRT Inc.
668.00
-29.00
-4.16%
JP:6545
internet infinity INC.
618.00
131.66
27.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 18, 2025